LUTATHERA: Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.
Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
| Facility | City | Region | Status |
|---|---|---|---|
| Banner MD Anderson Cancer Center | Phoenix | Arizona | |
| The Ohio State University Wexner Medical Center | Portland | Ohio | |
| Oregon Health & Sciences University Hospital | Portland | Oregon | |
| Virginia Mason in Seattle | Seattle | Washington | |
| Novartis Investigative site | Clichy | France | |
| Novartis Investigative site | Lyon | France | |
| Novartis Investigative site | Villejuif | France | |
| Novartis Investigative site | Coimbra | Coimbra District | |
| Novartis Investigative site | Santiago de Compostela | La Corunya | |
| Novartis Investigative site | Majadahonda | Madrid | |
| Novartis Investigative site | Birmingham | United Kingdom | |
| Novartis Investigative site | Cambridge | United Kingdom | |
| Novartis Investigative site | Glasgow | United Kingdom | |
| Novartis Investigative site | Liverpool | United Kingdom | |
| Novartis Investigative site | London | United Kingdom | |
| Novartis Investigative site | London | United Kingdom | |
| Novartis Investigative site | London | United Kingdom | |
| Novartis Investigative site | London | United Kingdom | |
| Novartis Investigative site | Manchester | United Kingdom | |
| Novartis Investigative site | Sheffield | United Kingdom |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03691064 on ClinicalTrials.gov ↗ ← All trials in the UK